The Venture Codex Logo

The Venture Codex

Overview

Specialty pharmaceutical company developing organ rejection prevention drug

Founded

2002

Deals · 12mo

0

Stage focus

Seed

Geographic focus

Switzerland
The Netherlands

Sector focus

Biotechnology
Health Care
Medical
Pharmaceutical

Investment portfolio

2rounds
NAMEDATESIZE
Xenikos
Sep 2021Led
$48 MOther Equity
MeduSoil
Dec 2020Participated
$2 MSeed
Xenikos
Sep 2021Led
$48 MOther Equity
MeduSoil
Dec 2020Participated
$2 MSeed
2
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Veloxis Pharmaceuticals: 2 funding rounds are recorded in the selected participation categories.All available history.
Veloxis Pharmaceuticals: 2 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Seed01
Other Equity10

Monthly Deal Activity

Veloxis Pharmaceuticals: 2 deals are recorded across 71 months.All available history.
Veloxis Pharmaceuticals: 2 deals are recorded across 71 months. All available history
MonthDeals
Dec '201
Jan '210
Feb '210
Mar '210
Apr '210
May '210
Jun '210
Jul '210
Aug '210
Sep '211
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Veloxis Pharmaceuticals: Health & Life Sciences is the largest displayed sector by deal count (1 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Veloxis Pharmaceuticals: Health & Life Sciences is the largest displayed sector by deal count (1 deals). All available history
SectorDeals
Health & Life Sciences1
Space & Frontier Tech1

Deal Size Distribution

Veloxis Pharmaceuticals: 2 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Veloxis Pharmaceuticals: 2 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M1
$5M-$10M0
$10M-$25M0
$25M-$50M1
$50M-$100M0
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Veloxis Pharmaceuticals: Europe has the largest recorded deal count among the displayed regions (2 deals).All available history.

Top 1 of 1 regions; European countries are grouped as Europe.

Veloxis Pharmaceuticals: Europe has the largest recorded deal count among the displayed regions (2 deals). All available history
RegionDeals
Europe2
Veloxis Pharmaceuticals: 6 co-investors are shown, with Medicxi sharing 1 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Veloxis Pharmaceuticals: 6 co-investors are shown, with Medicxi sharing 1 recorded deals. All available history
Co-investorShared deals
Medicxi1
Oost NL1
RA Capital Management1
Realstone Holding1
Sanquinnovate1
Schwartzkopff Partners1

Investment Strategy

Veloxis Pharmaceuticals: Led accounts for 50% and participating for 50% of round participation.All available history.
Veloxis Pharmaceuticals: Led accounts for 50% and participating for 50% of round participation. All available history
CategoryDeals (count)Share (%)
Led150%
Participating150%
Veloxis Pharmaceuticals: Single-lead accounts for 100% and co-led for 0% of lead dynamics.All available history.
Veloxis Pharmaceuticals: Single-lead accounts for 100% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead1100%
Co-led00%

Team

Christina Sylvest

SVP, Global Clinical Development & Operations

Mark Hensley

Chief Executive Officer

Thomas Dyrberg

Deputy Chairman and Director

Tunde Otulana

Chief Medical Officer

Ulf Meier-Kriesche

Chief Scientific Officer

William J. Polvino

President, CEO